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Two systematic reviews of literature have been conducted. One focused on the
efficacy, identifying health technology agencies reports, meta-analysis, systematic
reviews, and randomized controlled trials (RCTs). The safety systematic review
included the previous designs plus observational studies. In the latter review, stud-
ies in subsequent lines of treatment were considered. Searches were done in MED-
LINE, EMBASE, CRD, and the Cochrane Library until the 8th of June. The quality
assessment of the studies was done with the SIGN and CASPe tools. Two authors
independently selected the studies, assessed the quality, and performed the data
extraction, with disagreements resolved by a third reviewer until consensus was
obtained. RESULTS: In the efficacy systematic review, three RCTs were included.
The chemotherapy in one of these trials was FOLFIRI, in another trial FOLFOX-4,
and in the other one was oxaliplatin and fluoropyrimidine chemotherapy. In the
safety systematic review, five RCTs (3 studies in first-line, one study in second-line
and another with cetuximab in monotherapy in subsequent lines), and an obser-
vational study were considered. Cetuximab in combination with FOLFIRI improved
overall survival (OS), resection rate, progression free survival (PFS) and overall
tumour response rate (RR). Whereas, an increase in terms of OS was not observed
with cetuximab in combination with oxaliplatin based regimen, and different re-
sults were obtained in PFS. The only benefit observed with the later regimen was in
the RR. In terms of safety, cetuximab increased grade 3 or 4 skin toxicity.
CONCLUSIONS: The benefit of the addition of cetuximab to standard therapy for
previously untreated mCRC, KRAS wild-type patients differs depending on the
chemotherapy associated, with an improvement in all the outcomes when FOLFIRI
is used.
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OBJECTIVES: 5-hydroxytryptamine3 receptor antagonists (5-HT3 RAs) are used for
prophylaxis of chemotherapy-induced nausea and vomiting (CINV). This study
compared the risk of severe CINV associated with hospitalization or emergency
room admission among patients with lymphoma initiated and maintained on
palonosetron versus the other 5-HT3 RAs (granisetron, ondansetron, and
dolasetron).METHODS:Adult patients diagnosed with lymphoma and treated with
cyclophosphamide were selected from PharMetrics claims data (2005-2009). Other
inclusion criteria were continuous patient enrollment for at least6 months before
the initial diagnosis and receipt of 5-HT3 RA for CINV prevention on the day of
cyclophosphamide treatment (index date). CINV was identified by ICD-9-CM claims
for nausea, vomiting, and/or dehydration. Risk of CINV during the follow-up period
of 6 months from index date was assessed using multiple regression models, con-
trolling for age, gender, Charlson Comorbidity Index (CCI), and total dose of
cyclophosphamide. RESULTS: A total of 2609 patients were studied. Palonosetron
patients (n979; 37.5%) were older than the other 5-HT3 RAs (62.1 13.6 vs. 59.0
14.1 years, p0.0001), with similar CCI and gender. During follow-up, palonosetron
patients received more cyclophosphamide dose in significantly fewer CT days
(586 mg; p0.0005 and -0.73 days, both p0.0001), and had fewer patients expe-
riencing unadjusted severe CINV (7.3% vs. 10.4%, p0.007) as compared to the other
5-HT3 RA patients. Multiple regressions found that palonosetron group (versus the
other 5-HT3 RA group) experienced fewer CINV claims (0.47 less; p0.0253), fewer
CINV days (48% less; p0.0006), and a 34% lower severe CINV risk (Odds Ratio0.66;
p0.006). CONCLUSIONS: Patients in palonosetron group received higher CT dose
within fewer CT days and experienced significantly lower risk for potentially costly
CINV events than patients on other 5-HT3-RA-based antiemetic prophylaxis. Fur-
ther studies on the clinical and economic impact of the choice of 5-HT3-RA for CINV
prophylaxis in patients with lymphoma are needed.
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OBJECTIVES: Palonosetron, dolasetron, granisetron, and ondansetron [5-HT3 re-
ceptor antagonists (5-HT3-RAs)] are indicated to prevent chemotherapy-induced
nausea and vomiting (CINV). This study assessed the risk of uncontrolled CINV
following antiemetic prophylaxis with palonosetron  dexamethasone (group 1)
versus any of the other 5-HT3-RAs  dexamethasone (group 2) among single-day
HEC cycles in cancer diagnosed patients. METHODS: Single-day HEC cycles (a gap
of at least 5 days between 2 administrations) among patients with a cancer diag-
nosis and initiating antiemetic prophylaxis with group 1 versus group 2 between
June 1, 2006 to June 30, 2010 were identified from the IMS LifeLink claims database.
Uncontrolled CINV events were defined as nausea, vomiting, or dehydration ICD-
9-CM codes, hydration CPT codes, rescue medications, and/or use of antiemetic
therapy from days 2-5 post-HEC administration. Risk for an uncontrolled CINV
event was analyzed at cycle level using a logistic multivariate regression model
controlling for key variables. RESULTS: A total of 67,873 group 1 and 26,540 group 2
cycles (17,272 and 7,365 patients, respectively) were analyzed. Groups 1 and 2 were
similar in age [mean (sd): 55.0 (12.3) vs. 55.3 (12.6) years; p0.1502], Charlson co-
morbidity score [6.2 (3.2) vs. 6.2 (3.2); p0.7949], and female distribution (74.7% vs.
73.7%; p0.0893). Versus group 2, group 1 patients had a higher percent of breast
cancer (45.0% vs. 42.2%; p0.0001) and a lower percent of lymph/hematologic ma-
lignancies (11.6% vs. 13.4%; p0.0002). Group 1 cycles had a significantly lower
unadjusted risk of an uncontrolled CINV event (14.1% vs. 15.4%; p0.0001), while
the regression analysis predicted a 10% lower risk for group 1 cycles [Odds Ratio:
0.90 (95% CI: 0.86 – 0.93); p0.0001]. CONCLUSIONS: In this retrospective claims
data analysis, patients with cancer receiving single-day HEC cycles and group 1
prophylaxis for CINV had a lower risk for an uncontrolled CINV event versus group
2 prophylaxis.
PCN6
IMPACT OF 5-HT3 RECEPTOR ANTAGONIST SELECTION WITHIN TRIPLE
ANTIEMETIC REGIMENS ON THE RISK OF UNCONTROLLED CHEMOTHERAPY-
INDUCED NAUSEA IN PATIENTS WITH CANCER TREATED WITH HIGHLY
EMETOGENIC CHEMOTHERAPY
Schwartzberg L1, Jackson J2, Jain G2, Balu S3
1Accelerated Community Oncology Research Network, Memphis, TN, USA, 2Xcenda, LLC., Palm
Harbor, FL, USA, 3Eisai, Inc., Woodcliff Lake, NJ, USA
OBJECTIVES: Palonosetron, dolasetron, granisetron, and ondansetron [5-HT3 re-
ceptor antagonists (5-HT3-RAs)] are indicated to prevent chemotherapy-induced
nausea and vomiting (CINV). This study assessed the risk of uncontrolled CINV
following antiemetic prophylaxis with palonosetron  dexamethasone (group 1)
versus any of the other 5-HT3-RAs  dexamethasone (group 2) among single-day
HEC cycles in cancer diagnosed patients. METHODS: Single-day HEC cycles (a gap
of at least 5 days between 2 administrations) among patients with a cancer diag-
nosis and initiating antiemetic prophylaxis with group 1 versus group 2 between
June 1, 2006 to June 30, 2010 were identified from the IMS LifeLink claims database.
Uncontrolled CINV events were defined as nausea, vomiting, or dehydration ICD-
9-CM codes, hydration CPT codes, rescue medications, and/or use of antiemetic
therapy from days 2-5 post-HEC administration. Risk for an uncontrolled CINV
event was analyzed at cycle level using a logistic multivariate regression model
controlling for key variables. RESULTS: A total of 67,873 group 1 and 26,540 group 2
cycles (17,272 and 7,365 patients, respectively) were analyzed. Groups 1 and 2 were
similar in age [mean (sd): 55.0 (12.3) vs. 55.3 (12.6) years; p0.1502], Charlson co-
morbidity score [6.2 (3.2) vs. 6.2 (3.2); p0.7949], and female distribution (74.7% vs.
73.7%; p0.0893). Versus group 2, group 1 patients had a higher percent of breast
cancer (45.0% vs. 42.2%; p0.0001) and a lower percent of lymph/hematologic ma-
lignancies (11.6% vs. 13.4%; p0.0002). Group 1 cycles had a significantly lower
unadjusted risk of an uncontrolled CINV event (14.1% vs. 15.4%; p0.0001), while
the regression analysis predicted a 10% lower risk for group 1 cycles [Odds Ratio:
0.90 (95% CI: 0.86 – 0.93); p0.0001]. CONCLUSIONS: In this retrospective claims
data analysis, patients with cancer receiving single-day HEC cycles and group 1
prophylaxis for CINV had a lower risk for an uncontrolled CINV event versus group
2 prophylaxis.
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OBJECTIVES: The incidence of febrile neutropenia (FN) depends on the cancer type
and the chemotherapy regimen used. In Belgium, reimbursement of granulocyte-
colony stimulating factors (G-CSF) in primary prophylaxis against FN is limited to 4
indications. This study aimed to provide real-life information on the incidence and
impact of FN in chemotherapy-cancer combinations excluded from G-CSF primary
prophylaxis reimbursement. METHODS: Based on ICD-9 code and drug name all
chemotherapy-cancer combinations with at least one patient having an ICD-9 code
corresponding to neutropenia (288.0) and/or fever (780.6) and where G-CSF primary
prophylaxis was not reimbursed, were retrieved from the IMS Hospital Disease
database for the period 2005-2008. This database includes longitudinal (per calen-
dar year) information on diagnoses and drugs prescribed in about 34% of all Belgian
hospital beds. Incidence of FN (cases of FN with chemo-cancer combination di-
vided by total number of patients with this chemo-cancer combination), mortality
in patients with and without FN and impact of FN on subsequent chemotherapy
treatment decisions were assessed. RESULTS: Among the 25,544 patients at risk,
3,191 (13%) had at least one FN episode. Highest incidence rates were found in
combinations of cisplatin-containing regimens with head and neck (71/287, 25%),
stomach (24/110, 22%) and esophagus (36/202, 18%) cancers, lung cancers treated
with cisplatin-etoposide (52/292, 18%) or carboplatin-etoposide (102/659, 16%) reg-
imen and multiple myeloma treated with doxorubicin-vincristine regimen (26/152,
17%). Overall, 50% of first FN episodes occurred during cycle 1. Of the 3191 FN
patients 11% died, 24% switched chemotherapy regimen and 22% stopped treat-
ment during the cycle with FN. FN occurred subsequently in 27% of 1367 patients
continuing the same regimen. CONCLUSIONS: This study suggests clinically sig-
nificant FN-incidence is associated with chemotherapy regimens where G-CSF pri-
mary prophylaxis is not reimbursed in Belgium, which may lead to negative out-
comes in terms of mortality and treatment disruption.
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OBJECTIVES: This is a retrospective cohort study examining the development of
prolonged neutropenia as a result of the induction chemotherapy R-CHOP/CHOP in
diffuse large B-cell lymphoma (DLBCL) patients. It aims to 1) identify the incidence
and predictive factors of the prolonged neutropenia, and 2) evaluate the infection
complications and clinical outcomes of prolonged neutropenia in this patient
group. METHODS: Medical records of 43 DLBCL patients who received R-CHOP/
CHOP induction treatment between the year 2000 and 2010 at Prince of Wales
Hospital (PWH) were reviewed. Information including basic demographic informa-
tion, disease-related characteristics, and laboratory values were recorded. Inci-
dence of prolonged neutropenia, duration of neutropenic episodes, and infection
complication and outcomes were also collected. Correlations between possible
predictive/risk factors and the occurance of prolonged neutropenia were examined
using univariate analysis and multivariate logistic regression analysis. RESULTS:
Inpatient status (OR: 12.000, p-value  0.006), Ann Arbor stage III or IV (OR: 3.886,
p-value 0.049) and International Prognostic Index (IPI) high risk group (OR: 5.257,
p-value  0.020) were identified as predictive factors of prolonged neutropenia.
Prolonged neutropenia has been shown to cause significant longer duration of
hospitalization, increased ICU admission, dose reduction and delay in chemother-
apy or even early termination of treatment. The use of prophylactic G-CSF and/or
antibiotics has also been shown to reduce the occurrence of prolonged
neutropenia. CONCLUSIONS: Several predictive factors were demonstrated to
have association with the occurrence of prolonged neutropenia in DLBCL patients
after receiving R-CHOP/CHOP. Preventive measures, including prophylactic G-CSF
and/or antibiotics, should be considered as part of the treatment for the patients at
risk.
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OBJECTIVES: The monoclonal antibodies (mAbs) bevacizumab (Bmab), cetuximab
(Cmab), and panitumumab (Pmab) have been indicated for the treatment of pa-
tients with metastatic colorectal cancer (mCRC). The objective of this study was to
describe the incidence of adverse events (AEs) among patients with mCRC treated
in clinical practice. METHODS: Medical chart review was conducted for patients
treated at three US cancer centers from January 2004 to March 2009. Qualifying
cases were adults with: a diagnosis of colorectal cancer AND evidence of metastasis
AND receiving mAb therapy. AEs that were listed in mAb package inserts were
examined in the medical records. Grade 3/4 AEs occurring during mAb treatment
that were due to or possibly due to the mAb were identified. The Incidence of AEs
is reported across all patients and with each specific mAb. RESULTS: Among 103
patients with mCRC, 54 experienced 139 AEs that met study criteria. The overall
study sample was predominately Caucasian (99%), average age 57.6 years, 51.5%
female, and located in the Northeast (28.2%) and Midwest (70.9%). The majority of
patients (87%) were on chemotherapy. Grade 3/4 AEs that occurred with a fre-
quency 5% were: rash (24%) (Bmab 11%, Cmab 33%, Pmab 25%), diarrhea (18%)
(Bmab 14%, Cmab 17%, Pmab 15%), neutropenia (15%) (11% for Bmab and Cmab, 0%
for Pmab), vomiting/nausea (9%) (Bmab 5%, Cmab 7%, Pmab 5%), infusion reaction
(8%) (Bmab 3%, Cmab 13%, Pmab 0%), and venous thrombosis (7%) (8% for Bmab, 0%
for Cmab and Pmab). CONCLUSIONS: In this study of patients treated in commu-
nity practices, the incidences of AEs with mAb therapies in patients with mCRC had
similar patterns as those reported in the individual FDA labels. The findings could
be confounded by differences in time on therapy among mAbs. Additional research
with larger sample sizes is needed to more thoroughly examine these AEs in clin-
ical practice.
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OBJECTIVES: Currently, data regarding the prevalence of cardiovascular comor-
bidities in patients with metastatic colorectal cancer (mCRC) are limited. This
study determined the rate of comorbid cardiovascular diseases in patients with
mCRC, as comorbidities may impact treatment decisions, prognoses, and quality of
care.METHODS: From the PHARMO Record Linkage System (RLS), including among
other things, drug dispensing and hospitalization records of approximately 3.2
million residents in the The Netherlands, all patients with a primary or secondary
hospital discharge code for CRC and distant metastasis between 2000 and 2008
were selected and defined as patients with mCRC. The first discharge diagnosis
defining metastases served as the index date. Prevalent cardiovascular comorbidi-
ties were assessed during the 12 months prior to the index date and patients were
required to be registered in the PHARMO RLS during this period to be included in
the study cohort. Cardiovascular comorbidities were captured using both cardio-
vascular drug use and hospital admission data. RESULTS: A total of 2,964 patients
with mCRC were included in the analysis. Mean ( standard deviation) age at
diagnosis was 68 ( 12) years and 53% were male. Overall, cardiovascular comor-
bidities were observed in 52% of the patients. Of all patients identified by drug use
(n1,479), the most commonly used agents were antithrombotic agents (54%), fol-
lowed by beta blocking agents (46%), and agents acting on the renin-angiotensin
system (45%). Of the patients who were hospitalized for cardiovascular comorbidi-
ties during the year prior to index date (n297), about one-third was hospitalized
for cardiac dysrhythmia (39%), followed by congestive heart failure (19%) and hy-
pertension (18%). CONCLUSIONS: Cardiovascular comorbidities are commonly
seen in patients with mCRC, which might be explained by the high mean age at
diagnosis. Consideration of these conditions should be an integral part of the treat-
ment strategy in individual patients with mCRC.
PCN11
BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY FOR THE FIRST-LINE
TREATMENT OF METASTATIC COLORECTAL CANCER
Ubago R1, Castillo MA1, Flores S2, Beltrán C1
1Agencia de Evaluación de Tecnologías Sanitarias de Andalucía, Seville, Andalucia, Spain,
2Andalusian Agency for Health and Technology Assessment, Seville, Andalucia, Spain
Ubago R1, Castillo MA1, Flores S2, Beltrán C11Agencia de Evaluación de Tecnologías Sanitarias
de Andalucía, Seville, Andalucia, Spain, 2Andalusian Agency for Health and Technology
Assessment, Seville, Andalucia, Spain
OBJECTIVES: To assess the efficacy of bevacizumab plus chemotherapy compared
with chemotherapy alone in previously untreated metastatic colorectal cancer
(mCRC) patients, who are appropriated for intensive therapy.METHODS:A system-
atic review of the literature was conducted. The selection criteria of the studies for
this review were: health technology agencies reports, meta-analysis, systematic
reviews and randomized controlled trials (RCTs), in mCRC comparing chemother-
apy plus bevacizumab with chemotherapy alone. Searches were realized in MED-
LINE, EMBASE, the Cochrane Library, and CRD databases until the 8th of June 2011.
The end points evaluated were overall survival (OS), progression-free survival
(PFS), overall tumour response rate (RR), and quality of life (HRQoL). The selection of
the studies, quality assessment, data extraction and data analysis were done in-
dependently by two authors. Disagreements were resolved by a third reviewer until
consensus was obtained. RESULTS: Two RCTs comparing chemotherapy plus be-
vacizumab with chemotherapy alone for first-line treatment of mCRC were in-
cluded in the efficacy assessment. The chemotherapy in one of these trials was the
IFL regimen and in the other trial was XELOX/FOLFOX-4. The addition of bevaci-
zumab to IFL showed an increase in terms of OS (Hazard Ratio (HR): 0.66, p0.001),
PFS [HR: 0.54, p0.001], and RR. IFL is not current standard chemotherapy and it is
not an adequate comparator. The addition of bevacizumab to XELOX/FOLFOX-4
resulted in statistically significant difference in terms of PFS (HR: 0.83; Confidence
Interval 97.5%: 0.72-0.95). The median OS was not statistically significant, and the
RR was similar in both arms. No RCTs comparing bevacizumab with FOLFIRI vs.
FOLFIRI were found. None of the studies reported the impact of bevacizumab treat-
ment on HRQoL. CONCLUSIONS: The combination of bevacizumab with chemo-
therapy increases PFS in untreated mCRC, in patients who tolerate intensive ther-
apy. The improvement in terms of OS remains uncertain. OBJECTIVES: To assess
the efficacy of bevacizumab plus chemotherapy compared with chemotherapy
alone in previously untreated metastatic colorectal cancer (mCRC) patients, who
are appropriated for intensive therapy. METHODS: A systematic review of the lit-
erature was conducted. The selection criteria of the studies for this review were:
health technology agencies reports, meta-analysis, systematic reviews and ran-
domized controlled trials (RCTs), in mCRC comparing chemotherapy plus bevaci-
zumab with chemotherapy alone. Searches were realized in MEDLINE, EMBASE, the
Cochrane Library, and CRD databases until the 8th of June 2011. The end points
evaluated were overall survival (OS), progression-free survival (PFS), overall tu-
mour response rate (RR), and quality of life (HRQoL). The selection of the studies,
quality assessment, data extraction and data analysis were done independently by
two authors. Disagreements were resolved by a third reviewer until consensus was
obtained. RESULTS: Two RCTs comparing chemotherapy plus bevacizumab with
chemotherapy alone for first-line treatment of mCRC were included in the efficacy
assessment. The chemotherapy in one of these trials was the IFL regimen and in
the other trial was XELOX/FOLFOX-4. The addition of bevacizumab to IFL showed
an increase in terms of OS (Hazard Ratio (HR): 0.66, p0.001), PFS [HR: 0.54,
p0.001], and RR. IFL is not current standard chemotherapy and it is not an ade-
quate comparator. The addition of bevacizumab to XELOX/FOLFOX-4 resulted in
statistically significant difference in terms of PFS (HR: 0.83; Confidence Interval
97.5%: 0.72-0.95). The median OS was not statistically significant, and the RR was
similar in both arms. No RCTs comparing bevacizumab with FOLFIRI vs. FOLFIRI
were found. None of the studies reported the impact of bevacizumab treatment on
HRQoL. CONCLUSIONS: The combination of bevacizumab with chemotherapy in-
creases PFS in untreated mCRC, in patients who tolerate intensive therapy. The
improvement in terms of OS remains uncertain.
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OBJECTIVES: Chronic myeloid leukemia (CML) is a progressive disease consisting
of three phases: chronic, accelerated and blast crisis. Imatinib achieves high re-
sponse rates and improves prognosis. Dasatinib is a BCR-ABL kinase inhibitor ap-
proved for treating CML across all phases of disease. The present study modeled
the time to response, time to accelerated phase, blast crisis and death of newly
diagnosed patients with CML receiving first line therapy with dasatinib 100 mg/day
or imatinib 400 mg/day in the chronic phase. METHODS: A Markov simulation
model was developed using two cohorts of 200,000 CML patients treated with da-
satinib 100 mg/day or imatinib 400 mg/day. Health states included were complete
cytogenetic response (CCyR), major cytogenetic response (MCyR), no-response,
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